(Alliance News) - GlaxoSmithKline PLC said on Monday new data from its majority-owned specialist HIV company, ViiV Healthcare, reinforced the long-term efficacy and safety profiles of its HIV treatments.
North Carolina-based Viiv Healthcare will release data next week on its cabenuva treatment. Cabenuva on Tuesday was granted US Food & Drug Administration approval for every-two month use, for the treatment of HIV-1 in virologically suppressed adults. It is a combination of cabotegravir and rilpivirine drugs, each administered from an extended-release injectable suspension in a single-dose vial.
The new data will cover the evidence for this newly approved dose, including ATLAS-2M 152-week efficacy and safety findings. This builds upon the 96-week efficacy and safety data previously released. Viiv Healthcare will also present an investigator-sponsored analysis of adolescent perspectives to the treatment regimen.
The company will also release further data covering the efficacy of long-term use of dovato, a two-drug regimen of dolutegravir and lamivudine. This will include further 144-week findings from the Tango study, which has been evaluating the virologic response in patients receiving dovato versus those on tenofovir alafenamide based treatments.
The new data will be presented at the online Conference on Retroviruses and Opportunistic Infections, between February 12-16.
GSK holds a 78% stake in Viiv Healthcare, a joint venture with Pfizer Inc holding 12% and Shionogi Ltd 10%.
"The data to be presented at CROI includes study results of up to three years that reinforce the long-term efficacy and safety data of our long-acting medicines and 2-drug regimens. Despite the challenging environment we’ve faced for the last two years, ViiV Healthcare has continued to demonstrate leadership by bringing forward ground-breaking advances that offer people more options for HIV treatment and prevention," commented Viiv Healthcare Head of Research & Development Kimberly Smith.
Shares in GSK were up 0.2% to 1,635.40 pence each in London on Monday afternoon.
By Elizabeth Winter; elizabethwinter@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
Glaxosmithkline (GSK)
